Potential causes of variability in drug response include intrinsic factors such as ethnicity and
genetic differences in the expression of enzymes that metabolize drugs, such as those from …

Aim: CYP2C9 is one of the major drug metabolizing enzymes, however, little is known about
polymorphisms in CYP2C9 gene and pharmacological implications in Mexican indigenous …

Background and objective: The drug transporter MDR1 and the drug metabolizing enzyme
CYP3A are the two major biological factors determining the pharmacokinetics of many …

Abstract Cytochrome P450 3A4 (CYP3A4) is a key drug-metabolizing enzyme. Loss-of-
function variants have been reported as rare events, and the first demonstration of a …

Objective To determine the frequencies of two functional single nucleotide polymorphisms,
CYP3A5* 3 and CYP3A5* 6, in the CYP3A5 gene in three distinct Asian ethnic groups …

The genetic variability of the CYP1A1 I462V polymorphism (CYP1A1* 2C) was investigated
in four Brazilian populations: three groups of African descent and one group of European …

Allele frequency differences of functional CYP2C9 polymorphisms are responsible for some
of the variation in drug response observed in human populations. The most relevant …

Abstract Cytochrome P-450 3A4 (CYP3A4) contributes to the metabolism of approximately
half the drugs in clinical use today. The aim of the present study was to determine the …

Single nucleotide polymorphisms in CYP3A5 (A6986G) and MDR-1 (C3435T) genes have
been shown to be associated with the pharmacokinetics of tacrolimus in case of renal …

The influence of self-reported “race/color”, geographical origin and genetic ancestry on the
distribution of three functional CYP3A5 polymorphisms, their imputed haplotypes and …